Discrepancy in accelerated approvals for cancer drugs in the United States and Europe

被引：0
|
作者：
Nierengarten, Mary Beth
机构：
来源：
CANCER | 2024年 / 130卷 / 01期
关键词：
D O I：
10.1002/cncr.35138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, the discrepancy in accelerated approvals for cancer drugs in the United States and Europe comes down to the two countries having different lists of which approvals have been withdrawn, resulting in patient confusion. In addition, treatment with anticancer therapies increases the risk of developing a thromboembolic event in patients with cancer and COVID-19, and a new test for detecting cervical adenocarcinoma can find cancer that current Papanicolaou tests are less likely to pick up.
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [21] Orphan drugs: The current situation in the United States, Europe, and Asia
    Meyers A.S.
    Drug information journal : DIJ / Drug Information Association, 1997, 31 (1): : 101 - 104
  • [22] Cancer Screening And Age In The United States And Europe
    Howard, David H.
    Richardson, Lisa C.
    Thorpe, Kenneth E.
    HEALTH AFFAIRS, 2009, 28 (06) : 1838 - 1847
  • [23] Childhood cancer survival in Europe and the United States
    Gatta, G
    Capocaccia, R
    Coleman, MP
    Ries, LAG
    Berrino, F
    CANCER, 2002, 95 (08) : 1767 - 1772
  • [24] Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022
    Zhang, Xiaofang
    Peck, Carl C.
    Wang, Yaning
    Szucs, Thomas D.
    Sun, Wan
    Bai, Xue
    Chen, Siyu
    Wang, Fengzhi
    Wu, Yangfeng
    BMC MEDICINE, 2024, 22 (01):
  • [25] Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016
    MacEwan, Joanna P.
    Dennen, Syvart
    Kee, Rebecca
    Ali, Farzad
    Shafrin, Jason
    Batt, Katharine
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1558 - 1569
  • [26] Approvals of drugs with uncertain benefit-risk profiles in Europe
    Banzi, Rita
    Gerardi, Chiara
    Bertele, Vittorio
    Garattini, Silvio
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2015, 26 (08) : 572 - 584
  • [27] ORPHAN DESIGNATIONS AND APPROVALS IN THE EU, UNITED STATES AND JAPAN
    Korchagina, D.
    Tomita, N.
    Falissard, B.
    Toumi, M.
    Tavella, F.
    VALUE IN HEALTH, 2015, 18 (07) : A341 - A341
  • [28] AVAILABILITY OF BIOPHARMACEUTICALS AND CONVENTIONAL DRUGS IN THE UNITED-STATES, EUROPE AND JAPAN
    BIENZTADMOR, B
    SEO, PS
    BRYANT, N
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 166 - 166
  • [29] Clinical development of drugs for epilepsy: A review of approaches in the United States and Europe
    Porter, Roger J.
    Baulac, Michel
    Nohria, Virinder
    EPILEPSY RESEARCH, 2010, 89 (2-3) : 163 - 175
  • [30] Expensive Cancer Drugs: A Comparison between the United States and the United Kingdom
    Faden, Ruth R.
    Chalkidou, Kalipso
    Appleby, John
    Waters, Hugh R.
    Leider, Jonathon P.
    MILBANK QUARTERLY, 2009, 87 (04): : 789 - 819
12345